Associated Papers
MutationAssessor in cBioPortal.
Su Y et al.
Biorxiv : the Preprint Server for Biology, 2025
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Yasin F et al.
The Oncologist, 2024
Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.
Zheng S et al.
Molecular Biomedicine, 2024
Whole-exome sequencing of rectal neuroendocrine tumors.
Li Y et al.
Endocrine-related Cancer, 2023
The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer.
Shetty O et al.
South Asian Journal of Cancer, 2022
Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy.
Kim Y et al.
Cancer Cell International, 2021
The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients.
Fu X et al.
Frontiers in Oncology, 2021
BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer.
Conciatori F et al.
Communications Biology, 2020
Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma Identifies RAS and PIK3CA Mutations as Negative Survival Predictors.
Lai WA et al.
Cancers, 2020
The mutational landscape of normal human endometrial epithelium.
Moore L et al.
Nature, 2020
High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients.
Ishibashi T et al.
Diagnostics (basel, Switzerland), 2019
Racial Disparities in the Molecular Landscape of Cancer.
Heath EI et al.
Anticancer Research, 2018
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G et al.
Journal of Translational Medicine, 2016
Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G et al.
Oncotarget, 2015
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
Wang L et al.
Plos One, 2014
Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients.
Corso G et al.
European Journal of Human Genetics : Ejhg, 2013
Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
Ang D et al.
The Journal of Molecular Diagnostics : Jmd, 2013
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
Kitano S et al.
Plos One, 2013
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.
Palomba G et al.
Journal of Translational Medicine, 2012
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
Molinari F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
Janku F et al.
Plos One, 2011
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes.
Lurkin I et al.
Plos One, 2010
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations.
Nosho K et al.
Neoplasia (new York, N.y.), 2008
Detection of BRAF gene mutation in primary choroidal melanoma tissue.
Malaponte G et al.
Cancer Biology & Therapy, 2006
The prevalence of PIK3CA mutations in gastric and colon cancer.
Velho S et al.
European Journal of Cancer (oxford, England : 1990), 2005